These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 10819372)

  • 1. Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: a multivariate analysis.
    Bhatavdekar JM; Patel DD; Shah NG; Vora HH; Suthar TP; Chikhlikar PR; Ghosh N; Trivedi TI
    Ann Surg Oncol; 2000 May; 7(4):305-11. PubMed ID: 10819372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of biomarkers in squamous cell carcinoma of the tongue: multivariate analysis.
    Vora HH; Shah NG; Patel DD; Trivedi TI; Chikhlikar PR
    J Surg Oncol; 2003 Jan; 82(1):34-50. PubMed ID: 12501167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of CD44: a useful independent predictor of prognosis in patients with colorectal carcinomas.
    Bhatavdekar JM; Patel DD; Chikhlikar PR; Trivedi TI; Gosalia NM; Ghosh N; Shah NG; Vora HH; Suthar TP
    Ann Surg Oncol; 1998 Sep; 5(6):495-501. PubMed ID: 9754757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates.
    Nakopoulou L; Vourlakou C; Zervas A; Tzonou A; Gakiopoulou H; Dimopoulos MA
    Hum Pathol; 1998 Feb; 29(2):146-54. PubMed ID: 9490274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67.
    Mack L; Kerkvliet N; Doig G; O'Malley FP
    Hum Pathol; 1997 Aug; 28(8):974-9. PubMed ID: 9269835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical expression of bcl-2 in UICC stage I and III colorectal carcinoma patients: correlation with c-erbB-2, p53, ki-67, CD44, laminin and collagen IV in evaluating prognostic significance.
    Zavrides H; Zizi-Sermpetzoglou A; Elemenoglou I; Papatheofanis I; Peros G; Athanasas G; Panousopoulos D
    Pol J Pathol; 2006; 57(3):149-59. PubMed ID: 17219742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Survival of patients with laryngeal cancer and some prognostic factors].
    Gryczyński M; Kobos J; Murlewska A; Pietruszewska W
    Otolaryngol Pol; 2003; 57(3):329-40. PubMed ID: 14524174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients.
    Ozretic P; Alvir I; Sarcevic B; Vujaskovic Z; Rendic-Miocevic Z; Roguljic A; Beketic-Oreskovic L
    Int J Biol Markers; 2018 Jan; 33(1):109-115. PubMed ID: 28777433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
    Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
    J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of CD44 and c-erb-B2 protein overexpression in patients with gastric cancer.
    Doventas A; Bilici A; Demirell F; Ersoy G; Turna H; Doventas Y
    Hepatogastroenterology; 2012 Oct; 59(119):2196-201. PubMed ID: 23435135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
    Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
    Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apoptotic index correlates to bcl-2 and p53 protein expression, histological grade and prognosis in invasive breast cancers.
    Zhang GJ; Kimijima I; Abe R; Watanabe T; Kanno M; Hara K; Tsuchiya A
    Anticancer Res; 1998; 18(3B):1989-98. PubMed ID: 9677455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular markers are predictors of recurrence and survival in patients with Dukes B and Dukes C colorectal adenocarcinoma.
    Bhatavdekar JM; Patel DD; Chikhlikar PR; Shah NG; Vora HH; Ghosh N; Trivedi TI
    Dis Colon Rectum; 2001 Apr; 44(4):523-33. PubMed ID: 11330579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival.
    Rosati G; Chiacchio R; Reggiardo G; De Sanctis D; Manzione L
    Tumour Biol; 2004; 25(5-6):258-63. PubMed ID: 15627889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis.
    Pellikainen MJ; Pekola TT; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
    J Clin Pathol; 2003 Mar; 56(3):214-20. PubMed ID: 12610102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2.
    Vollmer RT; Humphrey PA; Swanson PE; Wick MR; Hudson ML
    Cancer; 1998 Feb; 82(4):715-23. PubMed ID: 9477105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Non-functioning pituitary adenomas: clinical features and immunohistochemistry].
    Ferreira JE; de Mello PA; de Magalhães AV; Botelho CH; Naves LA; Nosé V; Schmitt F
    Arq Neuropsiquiatr; 2005 Dec; 63(4):1070-8. PubMed ID: 16400431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
    Malamou-Mitsi V; Gogas H; Dafni U; Bourli A; Fillipidis T; Sotiropoulou M; Vlachodimitropoulos D; Papadopoulos S; Tzaida O; Kafiri G; Kyriakou V; Markaki S; Papaspyrou I; Karagianni E; Pavlakis K; Toliou T; Scopa C; Papakostas P; Bafaloukos D; Christodoulou C; Fountzilas G
    Ann Oncol; 2006 Oct; 17(10):1504-11. PubMed ID: 16968874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COX2 overexpression is a prognostic marker for Stage III breast cancer.
    Kim HS; Moon HG; Han W; Yom CK; Kim WH; Kim JH; Noh DY
    Breast Cancer Res Treat; 2012 Feb; 132(1):51-9. PubMed ID: 21533532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.